FocalTherics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q2 2026 revenue reached $13.2 million, a 39% increase year-over-year from $9.5 million in Q2 2025.

Capital System Sales: 13 Focal One capital system sales, up 44% year-over-year.

Gross Margin: Improved to 55.6%, up from 51.1% in Q2 2025, attributed to lower system costs and a disciplined pricing strategy.

Operating Expenses: Increased to $15.4 million from $11.5 million in the prior year, contributing to a net loss.

Cash Position: Cash and cash equivalents rose to $21.5 million from $15 million in Q1 2026, bolstered by a $40 million equity offering expected to close on August 14, 2026.

Negative Shareholder Equity: Reported at negative $3.2 million due to recurring losses and fair value changes of warrants.

2Strategic Updates and Business Highlights

Transitioned from EDAP to FocalTherics, focusing exclusively on high-growth focal therapy.

Discontinued noncore ESWL and distribution businesses to streamline financial reporting.

U.S. Focal One procedure volumes grew 47% year-over-year, indicating strong adoption and utilization.

Notable sales included placements in prestigious institutions like Vanderbilt University Medical Center and Cleveland Clinic.

Submitted a 510(k) application to the FDA for FocalConnect, enhancing remote capabilities for training and collaboration.

Proposed CMS reimbursement increase of approximately 12% for HIFU procedures in 2027, marking the fifth consecutive annual increase.

3Forward Guidance and Outlook

Reiterated full-year 2026 revenue guidance for continuing HIFU operations between $50 million and $54 million.

Focus on expanding into new indications for benign prostatic hyperplasia (BPH) and endometriosis, with potential market opportunities exceeding $10 billion.

Continued emphasis on commercial execution and scaling operations in both U.S. and international markets.

4Bad News, Challenges, or Points of Concern

Operating losses increased, with a notable $6.3 million noncash charge impacting net results.

Negative shareholder equity raises concerns about financial stability amidst ongoing losses.

The discontinued operations segment saw a 34% revenue decline, reflecting strategic shifts and the termination of distribution agreements.

Potential headwinds from tougher year-over-year comparisons in procedure volume growth in the second half of 2026.

5Notable Q&A Insights

Management highlighted the strong pipeline with 300 qualified leads, including some from VA hospitals, indicating growth potential in government accounts.

Emphasis on the importance of training and onboarding new surgeons to enhance utilization rates.

Discussion on the histotripsy development program, with a timeline of 1-2 years for potential advancements.

Management expressed confidence in the upcoming HIFUSA study results, expected by the end of 2026 or early 2027, which could significantly impact the company's narrative. Overall, FocalTherics demonstrated strong growth metrics in Q2 2026, with strategic initiatives aimed at expanding its market presence and enhancing its product offerings. However, challenges related to operating losses and negative equity remain critical areas to monitor.